National Securities Corp analyst Ben Klieve reiterated a Buy rating on Marrone Bio (MBII) on November 13 and set a price target of $2.50. The company’s shares closed last Monday at $1.18, close to its 52-week low of $1.10.
According to TipRanks.com, Klieve is a 3-star analyst with an average return of 1.1% and a 50.5% success rate. Klieve covers the Consumer Goods sector, focusing on stocks such as AgroFresh Solutions, Yield10 Bioscience, and Limoneira Co.
Marrone Bio has an analyst consensus of Moderate Buy, with a price target consensus of $2.50, a 101.6% upside from current levels. In a report issued on November 13, H.C. Wainwright also maintained a Buy rating on the stock with a $2.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.92 and a one-year low of $1.10. Currently, Marrone Bio has an average volume of 121.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marrone Bio Innovations, Inc. engages in the provision of bio-based pest management and plant health products for the agricultural and water treatment markets. Its brand includes regalia, bio-tam, grandevo, venerate and majestene. The company was founded by Pamela G. Marrone on June 15, 2006 and is headquartered in Davis, CA.
